UnitedHealth Group is currently facing increased scrutiny and market pressure due to a civil fraud investigation by the Justice Department. The investigation focuses on the company's Medicare billing practices, specifically related to inflated payments based on questionable diagnoses. This investigation, combined with an existing antitrust probe and criticism from investor Bill Ackman, has significantly impacted UnitedHealth's stock value. Concerns about fraud and abuse within the healthcare sector, along with a potential bipartisan focus on regulatory oversight, contribute to the challenging environment for UnitedHealth. The article suggests that a broader crackdown on the industry could occur despite historical Republican support for Medicare Advantage. Ultimately, the multitude of negative headlines presents considerable risk for investors as the healthcare industry faces a potential turning point.

President Trump announced new tariffs on China due to their role in the fentanyl trade, increasing existing tariffs by 10%. These tariffs are intended to pressure China into curbing the export of fentanyl precursors. Similar tariffs were threatened against Canada and Mexico, but were delayed to allow for negotiations regarding drug smuggling. China has responded with retaliatory duties, and seeks a broader agreement with the U.S., not solely focused on fentanyl. Despite rising overdose deaths related to fentanyl, preliminary data indicates a recent decline in these fatalities. China has not yet offered concrete proposals to address U.S. concerns.